Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 7Sarcoma 4Dermatologic 3Lymphoid 2Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Lymphoma, T-Cell, Cutaneous 2Sezary Syndrome 1Mycosis Fungoides 1Melanoma 1

Interventions

aldesleukin 69Cyclophosphamide 50fludarabine phosphate 36fludarabine 30Interleukin-2 27incomplete Freund's adjuvant 22Ipilimumab 20Biopsy 20Specimen Handling 19Magnetic Resonance Spectroscopy 19MART-1 Antigen 15CTLA-4 Antigen 15sargramostim 14Nivolumab 13Filgrastim 13montanide ISA 51 12Sorafenib 12Interferon-alpha 11pembrolizumab 10trametinib 9Temozolomide 9Bevacizumab 9dabrafenib 8temsirolimus 7Sirolimus 7Gene Expression Profiling 7tanespimycin 6Paclitaxel 6Dacarbazine 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × O(6)-benzylguanine × Dermatologic × Clear all
NCT00961220 2018-05-22

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
17 enrolled 6 charts
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00005961 2013-02-11

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled
Dermatologic

Melanoma

NCT00003613 2013-01-11

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
20 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡